Respiratory Medicine
Volume 104, Issue 8 , Pages 1121-1130 , August 2010

A 24-week comparison of low-dose ciclesonide and fluticasone propionate in mild to moderate asthma

  • Ronald Dahl

      Affiliations

    • Department of Respiratory Diseases & Allergy, Aarhus University Hospital, Nørrebrogada 44, 8000 Aarhus C, Denmark
    • Corresponding Author InformationCorresponding author. Tel.: +45 8949 2085; fax: +45 8949 2110.
    • ,
  • Renate Engelstätter

      Affiliations

    • Nycomed GmbH, Byk-Gulden-Str. 2, D-78467 Konstanz, Germany
    • ,
  • Ewa Trębas-Pietraś

      Affiliations

    • Department of Allergology, Cardinal Wyszyński Memorial Hospital, Al. Kraśnicka 100, 20-718 Lublin, Poland
    • ,
  • Piotr Kuna

      Affiliations

    • Department of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Kopcinskiego 22, 80-153 Lodz, Poland

Received 9 February 2010 ,Accepted 31 March 2010.

References 

  1. Masoli M, Fabian D, Holt S, Beasley R Global Initiative for Asthma (GINA) Program. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004;59(5):469–478
  2. Global Initiative for Asthma . Global strategy for asthma management and prevention. http://www.ginasthma.comDecember 2009;
  3. National HeartLung and Blood Institute . Expert panel report 3 (EPR3): guidelines for the diagnosis and management of asthma. http://www.nhlbi.nih.gov2007;
  4. Dahl R. Ciclesonide for the treatment of asthma. Ther Clin Risk Manag. 2006;2(1):25–38
  5. Deeks ED, Perry CM. Ciclesonide: a review of its use in the management of asthma. Drugs. 2008;68(12):1741–1770
  6. Langdon CG, Adler M, Mehra S, Alexander M, Drollmann A. Once-daily ciclesonide 80 or 320 μg for 12 weeks is safe and effective in patients with persistent asthma. Respir Med. 2005;99:1275–1285
  7. Pearlman DS, Berger WE, Kerwin E, LaForce C, Kundu S, Banerji D. Once-daily ciclesonide improves lung function and is well tolerated by patients with mild-to-moderate persistent asthma. J Allergy Clin Immunol. 2005;116(6):1207–1212
  8. Gauvreau GM, Boulet LP, Postma DS, Kawayama T, Watson RM, Duong M, et al. Effect of low-dose ciclesonide on allergen-induced responses in subjects with mild allergic asthma. J Allergy Clin Immunol. 2005;116(2):285–291
  9. Subbarao P, Duong M, Adelroth E, Otis J, Obminski G, Inman M, et al. Effect of ciclesonide dose and duration of therapy on exercise-induced bronchoconstriction in patients with asthma. J Allergy Clin Immunol. 2006;117(5):1008–1013
  10. Magnussen H, Hofman J, Staneta P, Lawo J-P, Hellwig M, Engelstätter R. Similar efficacy of ciclesonide once daily versus fluticasone propionate twice daily in patients with persistent asthma. J Asthma. 2007;44(7):555–563
  11. American Thoracic Society . Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis. 1987;136:225–244
  12. Fishman GS, Moore LR. A statistical evaluation of multiplicative congruential random number generators with modulus 231-1. J Am Stat Assoc. 1982;77:129–136
  13. American Thoracic Society . Standardization of spirometry – 1994 update. Am J Respir Crit Care Med. 1995;152:1107–1136
  14. Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax. 1992;47(2):76–83
  15. Juniper EF, Buist AS, Cox FM, Ferrie PJ, King DR. Validation of a standardized version of the Asthma Quality of Life Questionnaire. Chest. 1999;115(5):1265–1270
  16. Wolfe J, Rooklin A, Grady J, et al. Comparison of once- and twice-daily dosing of fluticasone propionate 200 micrograms per day administered by discus device in patients with asthma treated with or without inhaled corticosteroids. J Allergy Clin Immunol. 2000;105:1153–1161
  17. Buhl R, Vinkler I, Magyar P, et al. Comparable efficacy of ciclesonide once daily versus fluticasone propionate twice daily in asthma. Pulm Pharmacol Ther. 2006;19(6):404–412
  18. Boulet L-P, Bateman ED, Voves R, Müller T, Wolf S, Engelstätter R. A randomized study comparing ciclesonide and fluticasone propionate in patients with moderate persistent asthma. Respir Med. 2007;101(8):1677–1686
  19. Cohen J, Douma WR, ten Hacken NH, Vonk JM, Oudkerk M, Postma DS. Ciclesonide improves measures of small airway involvement in asthma. Eur Respir J. 2008;31(6):1213–1220
  20. Hoshino M. Comparison of effectiveness in ciclesonide and fluticasone propionate on small airway function in mild asthma. Allergol Int. 2010;59(1):59–66
  21. Wagner EM, Liu MC, Weinmann GG, Permutt S, Bleecker ER. Peripheral lung resistance in normal and asthmatic subjects. Am Rev Respir Dis. 1990;141(3):584–588
  22. Yanai M, Sekizawa K, Ohrui T, Sasaki H, Takishima T. Site of airway obstruction in pulmonary disease: direct measurement of intrabronchial pressure. J Appl Physiol. 1992;72(3):1016–1023
  23. Hamid Q, Song Y, Kotsimbos TC, Minshall E, Bai TR, Hegele RG, et al. Inflammation of small airways in asthma. J Allergy Clin Immunol. 1997;100(1):44–51
  24. Rohatagi S, Derendorf H, Zech K, Nave R, Banerji D. PK/PD of inhaled corticosteroids: the risk/benefit of inhaled ciclesonide. Allergy Clin Immunol. 2003;111(2 Suppl):[abstract] S218:598
  25. Newman S, Salmon A, Nave R, Drollmann A. High lung deposition of 99mTc-labeled ciclesonide administered via HFA-MDI to patients with asthma. Respir Med. 2006;100:375–384
  26. Ohbayashi H, Adachi M. Hydrofluoroalkane-beclomethasone dipropionate effectively improves airway eosinophilic inflammation including the distal airways of patients with mild to moderate persistent asthma as compared with fluticasone propionate in a randomized open double-cross study. Allergol Int. 2008;57(3):231–239
  27. Leach CL, Davidson PJ, Hasselquist BE, Boudreau RJ. Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone: a cross-over study in healthy volunteers. Chest. 2002;122(2):510–516
  28. Haahtela T, Järvinen M, Kava T, et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med. 1994;331(11):700–705
  29. van Grunsven PM, Dompeling E, van Schayck CP, Molema J, Folgering H, van Weel C. Treatment of mild asthma with inhaled corticosteroids: is discontinuation of therapy possible?. Fam Med. 1996;28(1):46–51
  30. British Thoracic Society . British guideline on the management of asthma. http://www.brit-thoracic.org.ukJune 2009;
  31. Buhl R, Berdel D, Criée C-P, Gillissen A, Kardos P, Kroegel C, et al. Guidelines for diagnosis and treatment of asthma patients. German Airway League and German Respiratory Society Pneumologie. 2006;60:139–183
  32. Boulet L-P, Turcotte H, Prince P, Lemière C, Olivenstein R, Laprise C, et al. Benefits of low-dose inhaled fluticasone on airway response and inflammation in mild asthma. Respir Med. 2009;103:1554–1563
  33. Chapman KR, Patel P, D’Urzo AD, Alexander M, Mehra S, Oedekoven C, et al. Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma. Allergy. 2005;60(3):330–337
  34. von Berg A, Engelstätter R, Minic P, et al. Comparison of the efficacy and safety of ciclesonide 160 microg once daily vs. budesonide 400 microg once daily in children with asthma. Pediatr Allergy Immunol. 2007;18(5):391–400
  35. Niphadkar P, Jagannath K, Joshi JM, Avad N, Boss H, Hellbardt S, et al. Comparison of the efficacy of ciclesonide 160 microg QD and budesonide 200 microg BID in adults with persistent asthma: a phase III, randomized, double-dummy, open-label study. Clin Ther. 2005;27(11):1752–1763
  36. Hansel TT, Benezet O, Kafé H, Ponitz HH, Cheung D, Engelstätter R, et al. A multinational, 12-week, randomized study comparing the efficacy and tolerability of ciclesonide and budesonide in patients with asthma. Clin Ther. 2006;28(6):906–920
  37. Friedman H, Wilcox T, Reardon G, Crespi S, Yawn BP. A retrospective study of the use of fluticasone propionate/salmeterol combination as initial asthma controller therapy in a commercially insured population. Clin Ther. 2008;30(10):1908–1917
  38. Friedman HS, Eid NS, Crespi S, Wilcox TK, Reardon G. Retrospective claims study of fluticasone propionate/salmeterol fixed-dose combination use as initial asthma controller therapy in children despite guideline recommendations. Clin Ther. 2009;31(5):1056–1063
  39. O’Byrne P, Barnes PJ, Rodriguez-Roisin R, Runnerstrom E, Sandstrom T, Svensson K, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med. 2001;164:1392–1397
  40. Ni CM, Greenstone IR, Ducharme FM. Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naïve adults. Cochrane Database Syst Rev. 2005;2:CD005307
  41. O’Byrne PM, Parameswaran K. Pharmacological management of mild or moderate persistent asthma. Lancet. 2006;368(9537):794–803
  42. Nathan RA, Kanter L, Ostrom NK. Ciclesonide improves health-related quality of life in adults and adolescents with mild-to-moderate persistent asthma. Allergy Asthma Proc. 2008;29(5):521–527
  43. Bateman ED, Linnhof AE, Homik L, Freudensprung U, Smau L, Engelstätter R. Comparison of twice-daily inhaled ciclesonide and fluticasone propionate in patients with moderate-to-severe persistent asthma. Pulm Pharmacol Ther. 2008;21(2):264–275
  44. Canonica GW, Baena-Cagnani CE, Blaiss MS, Dahl R, Kaliner MA, Valovirta EJ The GAPP Survey Working Group. Unmet needs in asthma: Global Asthma Physician and Patient (GAPP) Survey: global adult findings. Allergy. 2007;62:668–674

PII: S0954-6111(10)00150-2

doi: 10.1016/j.rmed.2010.03.032

Respiratory Medicine
Volume 104, Issue 8 , Pages 1121-1130 , August 2010

Article Tools

* Image Usage & Resolution